用于双等效抑制剂的多种链接器进行BET异形选择性:GSK785是一种BRD2/4-选择性双等效BET抑制剂
Francesco Rianjongdee1, Stephen J Atkinson1, Paul Bamborough1
1GSK, Stevenage, Hertfordshire SG1 2NY, U.K.
Journal of medicinal chemistry
|December 30, 2025
概括
研究人员开发了新的双价抑制剂,向和额外终端 (BET) 蛋白质. 他们发现了GSK785,这种分子可以选择性抑制BRD2和BRD4,同时节省BRD3,为改善癌症治疗提供了潜在的潜力.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 代蛋白和额外终端 (BET) 蛋白抑制是治疗癌症和炎症疾病的关键策略.
- 开发异型选择性抑制剂对于了解个体BET蛋白的功能和减少与泛BET抑制剂相关的副作用至关重要.
- 现有的泛BET抑制剂在临床应用中面临耐受性限制.
研究的目的:
- 设计和合成新型双价抑制剂,以实现布罗姆多马因和额外终端 (BET) 蛋白质异型选择性.
- 调查受约束的链接体几何结构对双价BET抑制剂的选择性概况的影响.
- 在BET蛋白家族成员中识别具有选择性向配置的特定抑制剂.
主要方法:
- 双价分子的设计和合成,使用结构受限的二胺作为连接剂.
- 使用两个由不同的链接器几何形状连接的BET绑定弹头.
- 在不同BET蛋白异型体中评估抑制剂配置.
主要成果:
- 布罗姆多马因和额外终端 (BET) 蛋白质异型表现出对具有多种链接设计的双价分子具有很高的适应性.
- 发现化合物9h (GSK785),一种新的双价抑制剂.
- GSK785表现出一种独特的BRD2/4选择性,BRD3节约性抑制特征.
结论:
- 具有受约束链接器的双对应抑制剂代表了实现布罗姆多马因和额外终端 (BET) 蛋白质异型选择性的可行策略.
- 已识别的抑制剂GSK785提供了一个有前途的治疗候选者,具有独特的选择性,可用于瘤学和免疫炎症疾病的潜在用途.
- 对GSK785的进一步研究可以阐明特定的治疗应用,并优化其临床潜力.
相关概念视频
Ligand Binding and Linkage
5.4K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.4K
Drug-Receptor Bonds
4.1K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
4.1K
Dipeptidyl Peptidase 4 Inhibitors
540
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
540
Protein Complexes with Interchangeable Parts
2.8K
Groups of proteins may form a complex where each protein in this complex has a different role in the overall execution of the complex’s function. Often some of the proteins in the complex can be replaced by a closely related variant to give a complex that contains many of the same components yet is functionally distinct.
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
2.8K


